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Abstract: As the key components of innate immunity, human host defense antimicrobial 
peptides and proteins (AMPs) play a critical role in warding off invading microbial 
pathogens. In addition, AMPs can possess other biological functions such as apoptosis, 
wound healing, and immune modulation. This article provides an overview on the 
identification, activity, 3D structure, and mechanism of action of human AMPs selected 
from the antimicrobial peptide database. Over 100 such peptides have been identified from 
a variety of tissues and epithelial surfaces, including skin, eyes, ears, mouths, gut, immune, 
nervous and urinary systems. These peptides vary from 10 to 150 amino acids with a net 
charge between −3 and +20 and a hydrophobic content below 60%. The sequence diversity 
enables human AMPs to adopt various 3D structures and to attack pathogens by different 
mechanisms. While α-defensin HD-6 can self-assemble on the bacterial surface into 
nanonets to entangle bacteria, both HNP-1 and β-defensin hBD-3 are able to block cell 
wall biosynthesis by binding to lipid II. Lysozyme is well-characterized to cleave bacterial 
cell wall polysaccharides but can also kill bacteria by a non-catalytic mechanism. The two 
hydrophobic domains in the long amphipathic α-helix of human cathelicidin LL-37 lays the 
basis for binding and disrupting the curved anionic bacterial membrane surfaces by 
forming pores or via the carpet model. Furthermore, dermcidin may serve as ion channel 
by forming a long helix-bundle structure. In addition, the C-type lectin RegIIIα can initially 
recognize bacterial peptidoglycans followed by pore formation in the membrane. Finally, 
histatin 5 and GAPDH(2-32) can enter microbial cells to exert their effects. It appears that 
granulysin enters cells and kills intracellular pathogens with the aid of pore-forming 
perforin. This arsenal of human defense proteins not only keeps us healthy but also inspires 
the development of a new generation of personalized medicine to combat drug-resistant 
superbugs, fungi, viruses, parasites, or cancer. Alternatively, multiple factors (e.g., albumin, 
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arginine, butyrate, calcium, cyclic AMP, isoleucine, short-chain fatty acids, UV B light, 
vitamin D, and zinc) are able to induce the expression of antimicrobial peptides, opening 
new avenues to the development of anti-infectious drugs. 
Keywords: antimicrobial chemokines; antimicrobial neuropeptides; antimicrobial proteins; 
cathelicidin LL-37; defensins; dermcidin; hepcidins; histatins; RNases 
 
1. Introduction 
Host defense antimicrobial peptides (AMPs) are key components of the innate immune system 
shared by both invertebrates and vertebrates. Invertebrates such as insects and crustaceans do not have 
adaptive immune systems and innate defense systems serve as the only protective mechanism. It is 
now appreciated that innate immune systems also play an indispensable role in vertebrates by directly 
killing invading microbes in the early stage. Later, vertebrate AMPs can also help augment the 
adaptive immune system to further handle infections. Thus, host defense peptides may have dual role: 
rapid microbial killing and subsequent immune modulation [1–6]. 
The universality of AMPs is evidenced by the identification of these molecules in a variety of 
organisms. Over 2,300 such peptides have been isolated and characterized according to the online 
updated Antimicrobial Peptide Database (APD) [7,8]. As of April 2014, there are 233 AMPs from 
bacteria (i.e., bacteriocins), six from protozoa, 12 from fungi, 306 from plants, and 1,801 host defense 
peptides from animals. AMPs are usually gene-coded and can be constitutively expressed or induced 
to fend off invading pathogens. In addition, some bacteria use a second mechanism to assemble 
peptide antibiotics by using a multiple-enzyme system, leading to distinct chemical modifications not 
observed in gene-coded cases. Most of the AMPs are cationic and short with less than 50 amino acids. 
Such features are ideal to target the negatively charged surface of bacteria [1–6]. 
AMPs also protect humans from microbial infection. They have been identified in a variety of 
exposed tissues or surfaces such as skin, eyes, ears, mouth, airways, lung, intestines, and the urinary 
tract. While human cathelicidin LL-37 is detected in the skin of new born infants [9], human  
beta-defensin 2 (hBD-2) is frequently expressed in older individuals. Human S100 proteins, hBD-2, 
human beta-defensin 3 (hBD-3), and cathelicidin are significantly higher in fetal keratinocytes than in 
postnatal skin cells [10]. In addition, psoriasin (S100A7), RNase 7, and hBD-3 are differentially 
expressed in healthy human skin [11]. When the skin barrier is broken, psoriasin is up-regulated [12]. 
Lysozyme and lactoferrin have been found in human tears [13]. In addition, β-defensins are expressed 
in human middle ear epithelial cells [14]. Drosomycin-like defensin (DLD) [15] is produced in human 
oral epithelial cells as part of host defense against fungal infection. Defensins, cathelicidins,  
and histatins are important in preventing oral cavity [16]. Apart from antimicrobial activity, human 
AMPs such as cathelicidins and defensins possess other functions such as immune modulation, 
apoptosis, and wound healing [1–6]. It is now recognized that certain defensins also play a critical role 
in sperm fertilization [17–19]. By the time this manuscript was completed, 103 human AMPs were 
found in the APD [7,8]. A selected set of these peptides is provided in Table 1. The lengths of these 
human peptides range from 10 (neurokinin A) to 149 amino acids (RegIIIα). Their net charges vary 
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from −3 (β-amyloid peptide) to +20 (antimicrobial chemokine CXCL9). On average, human AMPs 
have 55 amino acids with a net charge of +5.6. Thus, both the average length and net charge for the 
current list of human AMPs are higher than those averages from all the AMPs (32.4 residues and net 
charge +3.2). An important reason for this is the inclusion of human antimicrobial proteins (> 100 
amino acids) with high net charges (on average +10). The sequence diversity of human AMPs directly 
determines their structural and functional diversity. This review article highlights the discovery, activity, 
structure, mechanism of action, and therapeutic strategies of human host defense peptides selected 
from the APD. 
Table 1. Discovery timeline of select human antimicrobial peptides and proteins 1. 

































G, V, F, C [21] 
1988 Histatin 1  DSHEKRHHGYRRKFHEKHH
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1988 Histatin 3 DSHAKRHHGYKRKFHEKHH
SHRGYRSNYLYDN 
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Table 1. Cont. 




































intestine G+ [44] 
2008 Substance P RPKPQQFFGLM the nervous 
system 


























skin G, F [49] 





2012 KDAMP RAIGGGLSSVGGGSSTIKY eyes G- [51] 
2013 DEFB114 DRCTKRYGRCKRDCLESEKQI
DICSLPRKICCTEKLYEEDDMF 
epididymis G, F [19] 
1 Data from the APD [7,8]. For a complete list of human AMPs, please visit the APD website 
(http://aps.unmc.edu/AP) and search in the name field using “human”. 2 In the APD, antimicrobial activities 
against different types of microbes are annotated as below: G, bacteria; G+, Gram-positive bacteria only;  
G-, Gram-negative bacteria only; F, fungi; V, viruses; P, parasites; C, cancer cells.  
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2. Identification of Human Antimicrobial Peptides 
Antimicrobial substances might have been noticed long time ago [1–6]. Human lysozyme  
(130 amino acids), discovered in saliva by Alexander Fleming in 1922 [20], is recognized as the first 
antimicrobial protein [6]. However, the isolation and characterization of many more AMPs with 
defined amino acid sequences did not start until the 1980s (please refer to the annual AMP discovery 
plot in ref. [52]). Two major methods were utilized for AMP identification. Initially, chromatographic 
approaches were used to isolate and characterize new peptides. With the recognition of peptide 
sequence motifs, bioinformatic approaches were later developed to identify AMPs at the genomic 
level. In the following, we describe the discovery of the major families of human antibacterial peptides 
identified during 1985 and 2013. 
2.1. Human Defensins 
Host defense peptides are usually expressed as precursor proteins and the mature form is released 
by protease processing. In 1985, the Lehrer group isolated a family of the mature form of α-defensins 
from human blood [21]. Based on the source, property and size, these peptides were named as human 
neutrophil peptides (HNP-1, HNP-2, and HNP-3). The three defensins have nearly identical amino 
acid sequences (Table 1). Compared to HNP-2, both HNP-1 and HNP-3 contain only one additional 
amino acid residue at the N-terminus: alanine for HNP-1 and aspartate for HNP-3. This additional 
acidic residue in HNP-3 may make HNP-3 less active than HNP-1 or HNP-2 in killing Staphylococcus 
aureus, Pseudomonas aeruginosa, and Escherichia coli. A fourth human neutrophil defensin, HNP-4, 
was reported in 1989 [23]. It was also purified to homogeneity by chromatographic methods. HNP-4 
has a distinct peptide sequence with 33 amino acids. In vitro, purified HNP-4 was shown to kill E. coli, 
Streptococcus faecalis, and Candida albicans. Lehrer and colleagues found that HNP-1, HNP-2, and 
HNP-3 are abundant in bone marrow, and can be detected in peripheral blood leukocytes, spleen and 
thymus by RT-PCR [53]. 
In 1989, Ouellette and colleagues identified α-defensin genes from mouse Paneth cells [54]. Bevins 
hypothsized that such orthologs also exist in human epithelial cells as part of the host defense 
mechanism. A genetic approach was developed to map additional defensin genes based on the high 
conservation of the nucleotide sequences in the signal coding region as well as the untranslated 5′ 
region. Using the probes from the conserved regions, they cloned the gene of HD-5 from human Paneth 
cells [25]. Likewise, HD-6 was identified [26]. These peptides are tissue-specific as they are only 
expressed in the Paneth cells of human intestines. The six human α-defensins (Table 1) share the same 
disulfide bond pattern. If we number the six cysteines in Roman numbers: I, II, III, to VI, the three 
disulfide bonds in α-defensins are CI–CVI, CII–CIV, and CIII–CV. Interestingly, alpha defensins have 
been found in the neutrophils of rabbits, rats, hamsters, and guinea pigs, but not in mice or pigs [55]. 
Members from the human β-defensin family were discovered in the 1990s. Different from  
α-defensins, the three disulfide bonds in β-defensins are CI–CV, CII–CIV, and CIII–CVI. Also,  
β-defensins have a slightly longer sequence to allow for an additional helical region. The first human β 
defensin (hBD-1) was reported by Bensch et al. from human plasma in 1995 [27]. Quantitative mRNA 
analysis revealed kidney as the major source for hBD-1 [56]. In addition, different truncated forms of 
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hBD-1 were also isolated and found to be active against E. coli. The activity of hBD-1 might have been 
compromised in cystic fibrosis (CF) lung due to its salt-sensitive activity against P. aeruginosa [57]. 
Subsequently, hBD-2 was identified from lesional psoriatic skin using the whole E. coli affinity 
column [32]. This material was selected for AMP isolation based on the fact that patients with lesional 
psoriatic skin have fewer skin infections than expected. This peptide is effective in killing  
Gram-negative bacteria E. coli, P. aeruginosa, and yeast C. albicans, but is only bacteriostatic against 
Gram-positive S. aureus. Like hBD-1, the activity of HBD-2 is also salt-sensitive [58]. In 2001, both 
hBD-3 and hBD-4 were documented [37,38]. Based on this disulfide bond linkage pattern, hBD-3 was 
also identified by using a bioinformatic approach [59,60]. In contrast to hBD-1 and hBD-2, hBD-3 
remained active against S. aureus and vancomycin-resistant Enterococcus faecium at physiological salt 
concentrations [37]. Bioinformatic studies led to the identification of 28 additional human and 43 
mouse β-defensin genes in the respective genome [61]. Several of these β-defensins (hBD-6, hBD-26, 
hBD-27, hBD-28, and DEFB114) are indeed antimicrobial in vitro [62–64]. This sequence motif-based 
peptide prediction may be applied to any other species with a completed genome. 
In insects, the activation of TOLL directly leads to the expression of drosomycin against fungal 
infection [65]. In 2008, human drosomycin-like defensin was detected in oral mucosa [46,66], 
indicating that this ancient innate defense mechanism is conserved. Sequence alignment in the APD 
revealed 40% similarity to insect drosomycin, which comprises one α-helical and three β-strands. 
Therefore, such a combined structure resembles human β-defensins to some extent. This peptide 
appears to be specifically effective against filamentous fungi (e.g., Aspergillus spp) as it did not kill 
tested yeast, Gram-positive or Gram-negative bacteria. Although the connection pattern of the six 
cysteines has not yet elucidated, the resulting three disulfide bonds are critical for the antifungal 
activity of human drosomycin-like defensing [46]. 
It is interesting to mention that a different type of defensins (called θ-defensins) has been identified 
from non-human primates [66,67]. These 18-residue defensins are circular due to the formation of a 
peptide bond between the N- and C-terminal ends. Like α- and β-defensins, they are also stabilized by 
three sets of disulfide bonds (CI–CVI, CII–CV, and CIII–CIV). These defensins are generated by 
liganding two truncated α-defensins. These genes are not expressed in humans due to the existence of a 
premature stop codon. Like monkey θ-defensins, synthetic peptides corresponding to these human 
counterpart pseudogenes are HIV-1 inhibitory [68–70]. It is uncertain whether the loss of θ-defensins 
made humans generally more susceptible to HIV-1 infection. 
2.2. Human Histatins: Two Genes Multiple Peptides 
Histatins are a family of AMPs rich in histidines. In 1988, histatins 1, 3, and 5 were isolated from 
human saliva by size-exclusion chromatography followed by HPLC separation [22]. All three histatins 
exhibit the ability to kill the pathogenic yeast, C. albicans. Subsequently, other histatins were also 
isolated [71]. However, only histatins 1 and 3 are gene encoded [22,72], since others are the cleaved 
products of these two peptides. The histatin genes are located on chromosome 4, band q13 and 
exclusively expressed in human salivary secretions [73]. 
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2.3. Human Cathelicidins: One Gene Multiple Peptides  
The significance of cathelicidins in protecting humans from infection is established by data from 
animal models [74–76]. Cathelicidin peptides were first isolated in 1989 [77]. The precursor proteins 
of cathelicidins share a highly conserved N-terminal “cathelin” domain, but have drastically different 
antimicrobial sequences, ranging from Pro- and Arg-rich peptides, helical peptides, to disulfide-linked 
sequences [78]. The word “cathelicidin” was originally used to refer to the entire precursor protein. 
However, it is now accepted as the family name for mature AMPs from the C-terminal region. Another 
term hCAP-18 is abbreviated from human cationic protein of 18 kDa, representing the precursors prior 
to the release of cathelicidin peptides. However, these terms are interchangeably used in the literature. 
Based on the conserved sequences in the cathelicidin precursors, Agerberth and colleagues cloned 
the only human cathelicidin gene and predicted the antimicrobial peptide as FALL-39 in analogy to 
PR-39 discovered in cattle [28]. Using the probes designed based on rabbit CAP-18, Larrick et al. also 
cloned the C-terminal antimicrobial peptide [29]. In the same year, Cowland et al. isolated a 19 kDa 
precursor protein hCAP-18 from human neutrophils [30]. Subsequently, the European group isolated 
the natural form of the mature human cathelicidin peptide from neutrophils [79]. Since the isolated 
peptide contains 37 amino acids and starts with a pair of leucines, it was named LL-37, which is two 
residues shorter than the initially predicted peptide FALL-39 [28]. Interestingly, ALL-38, another form 
of human cathelicidin peptides, was also characterized in 2003 [80]. This alterative form contains one 
more alanine at the N-terminus than LL-37. ALL-38 was generated in female vagina due to the action 
of gastricsin on sperm hCAP-18. Antimicrobial assays revealed a similar activity spectrum for LL-37 
and ALL-38 against a panel of bacteria, including E. coli, S. aureus, P. aeruginosa, and Bacillus 
megaterium. Thus, ALL-38, as well as other active peptides such as SgI-29 [81], plays a defense role 
in the human reproductive system. In addition, LL-37 fragments were isolated from human skin  
by chromatographic approaches [82]. These fragments have varying activities compared to intact  
LL-37. Hence, a single human cathelicidin gene has been processed into different forms of active  
peptides [83]. This phenomenon, however, is not unique to humans. There is precedence that multiple 
AMPs are programmed in a single plant gene [84]. One possibility for this is that different cathelicidin 
fragments provide a means to expanding the functional space of the single human cathelicidin gene.  
A different model is utilized by sheep, horses, and cattle, which produce multiple cathelicidins with 
varying functions [85–88]. 
2.4. Human Dermcidin 
Besides human cathelicidin LL-37 [89], dermcidin, an anionic defense peptide, was found in human 
sweat [39]. Unlike human defensins and cathelicidins that are induced under inflammatory and injured 
conditions, dermcidin is constitutively expressed in human sweat [90]. Furthermore, dermcidin 
variants as well as fragments were also detected. It appears that the level of dermcidin did not vary 
between healthy people and infected patients [91]. In addition, dermcidin may be related to other 
human diseases such as cancer and atherosclerosis [92,93]. 
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2.5. Human Hepcidins 
Human liver expressed antimicrobial peptide-1 (LEAP-1) was discovered from human blood 
ultrafiltrate in 2000 [35]. The same peptide was also found by Ganz et al. from human urine and 
named as hepcidin 25 [94]. This liver-synthesized peptide is especially rich in cysteines (32%), leading 
to four disulfide bonds in a 25-residue peptide. In 2009, the connection pattern of the four disulfide 
bonds was revised to C7–C22, C10–C13, C11–C19, and C14–C22 [95]. This antimicrobial peptide 
also plays an important role in ferrous use [96] and single-residue mutations in this molecule are 
associated with severe juvenile hemochromatosis, a genetic disease of severe iron overload [97]. Unlike 
LEAP-1, antimicrobial peptide LEAP-2, however, is not involved in the regulation of iron use [98]. 
2.6. Human AMPs Derived from Known Proteins 
Some AMPs are derived from known proteins. Park et al. isolated buforin I from amphibians in 
1996 [99]. Sequence comparison revealed that buforin I is a cleaved fragment of histone H2A. Of 
interest, this mRNA was also detected in humans, suggesting a possible role of this peptide in 
antimicrobial defense [100]. 
The human airways are essential for the exchange of molecules with the environment. It is 
necessary to guard this channel to prevent the infection of microbes in the air. In 2001, Ganz and 
colleagues isolated calcitermin primarily targeting Gram-negative bacteria. This 15-residue peptide is 
derived from the C-terminus of calgranulin C (a S100 protein). It contains three histidines (His9, 
His11, and His13) at the N-terminus and has the potential to adopt a helical conformation in 
membranes. These histidines may explain its enhanced activity in acidic buffers (pH 5.4) and in the 
presence of micromolar concentrations of ZnCl2 [101]. 
Another example for protein-derived AMPs is KDAMP, keratin-derived AMPs, which were 
identified from bactericidal lysate fractions of human corneal epithelial cells. These molecules are rich 
in glycines [51]. The glycines appear to be important for killing P. aeruginosa as substitution of a 
string of glycines with alanines reduced peptide potency. A search of the APD reveals that glycine-rich 
(>25%) AMPs have also been identified in bacteria, plants, insects, spiders, nematodes, crustaceans, 
fish, and amphibians. Thus, glycine-rich peptides constitute a common molecular design for host 
defense [102–110]. 
2.7. Antimicrobial Chemokines and AMPs from Human Immune Cells 
The fact that some AMPs possess chemotactic effects inspired the evaluation of antimicrobial 
activity of chemokines, which are known for chemotaxis. In 2000, Krijgsveld et al. found antimicrobial 
thrombocidins, peptides derived from CXC chemokines in human blood platelets [34]. In 2003, 
Oppenheim and colleagues identified 20 antimicrobial chemokines [42] and additional two members 
(CCL27 and CCL28) were also reported by Hieshima and colleagues [111]. In 2011, antimicrobial 
activity of chemotactic chemerin was also reported [49]. Further studies are required to establish the  
in vivo relevance of the in vitro activity of these chemokines. The common nature of chemokines and 
AMPs, however, bridges the innate and adaptive immune systems. 
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Antimicrobial peptides have also been found in other immune cells. In 1999, Hiemstra et al. 
identified ubiquicidin from ribosomal protein S30 in various tissues. This peptide is active against 
Listeria monocytogenes, S. aureus, Salmonella typhimurium, and E. coli. Considering the fact that  
L. monocytogenes can live within cells, the expression of ubiquicidin in macrophages would limit the 
replication of this bacterium. Interestingly, ribosomal protein S30 is identical in rats, mice and  
humans [33]. In 1998, granulysin (74 amino acids) was detected in human cytotoxic T cells and natural 
killer (NK) cells [32]. Similar proteins called NK-lysins are found in other animals [112]. Granulysin 
is active against Gram-positive and Gram-negative bacteria, and fungi, including mycobacteria.  
Thus, the human adaptive immune system has incorporated an innate defense molecule for direct 
disruption of tumor cells or invading microbes. In addition, human γδ T cells produce antimicrobial 
peptide elafin [47]. Like human secretory leucoprotease inhibitor (SLPI), elafin was initially identified 
as a protease inhibitor. Elafin shows an inhibitory effect on bacteria, fungi, and viruses [113]. 
2.8. Antimicrobial Neuropeptides 
Antibacterial peptides were also isolated from the neuroendocrine system from cattle. Secretolytin 
corresponds to the C-terminal fragment (residues 614–626) of bovine chromogranin B [114]. This 
peptide displayed activity against M. luteus and reduced the growth of B. megaterium. Vasostatin-1 is 
a 76-residue N-terminal fragment of bovine chromogranin A. This peptide is active against both  
Gram-positive bacteria and fungi [115]. It is conserved in humans, pigs, horses, mice, rats, and frogs. 
Catestatin is a 21-residue AMP derived from human chromogranin A [116]. Subsequently, cattle 
enkelytin, the C-terminal fragment corresponding to residues 209–237 of proenkephalin-A was also 
found to be antibacterial [117]. A similar proenkephalin system exists in humans although the 
processing machinery can differ [118]. Thus, these neuropeptides also play a communication role 
between neuroendocrine and the immune system [119]. 
In 1998, human neuropeptide Y (36 residues) was demonstrated to have antimicrobial activity [120]. 
Interestingly, the antifungal activity of this peptide against C. albicans increased several folds by 
truncating N-terminal 12 residues, implying the importance of the helical region 14–32. A more recent 
study, however, only observed activity against E. coli, but not C. albicans [121]. Future studies will 
clarify whether the peptide has direct antimicrobial effects. In 1999, adrenomedullin, usually expressed 
on surface epithelial cells, was reported to have antibacterial activity against all the tested bacteria,  
but not C. albicans [122]. Alpha-MSH was added to the human AMP list in 2000 as well [36]. These 
findings extended host defense peptides to the nervous system [123]. Since then, more antimicrobial 
neuropeptides have been documented [45,124]. Some of these neuropeptides may become leads for 
developing new antibiotics. For example, alarin is a human brain neuropeptide with activity against 
only Gram-negative bacteria such as E. coli, but not Gram-positive bacteria such as S. aureus [124].  
In particular, α-MSH showed in vitro antifungal activity against C. albicans at fM to pM [125],  
much lower than nM for some bacterial lantibiotics and µM for many cationic peptides. 
2.9. Beta-Amyloid Peptides 
Beta-amyloid peptides have long been thought to be the culprit of Alzheimer's disease. It is believed 
that the β-sheet form, not the helical form of the peptide, is toxic. A recent demonstration of 
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antimicrobial activity for β-amyloid peptides adds a new research dimension to this worrisome  
disease [48]. Further studies along this line could be useful to provide novel insight into the 
mechanism of this human disease. In 2012, amylin (human islet amyloid polypeptide, hIAPP) was 
found bactericidal, too [50]. Transformation of amylin into toxic fibrils can disrupt cell membranes 
and lead to β-cell death, perhaps one of the causative factors of type 2 diabetes mellitus. The aggregated 
form of amylin is likely to exert its cytotoxicity by damaging cell membranes [126]. It is noticeable 
that, when in excess, bacteria microcin E492 can form fibrils as a storage form and lose antimicrobial 
activity [127]. Is there anything in common here from bacteria to humans? Perhaps, this is one 
mechanism that nature attempts to remove the toxic effects of an over expressed protein, including 
antimicrobial peptide. 
2.10. Human Antimicrobial Proteins 
There are 14 antimicrobial proteins (>100 amino acids) in the APD database as of March 2014 [8]. 
This includes the first antimicrobial protein lysozyme [20]. Several eosinophil proteins were purified 
in 1990. Both eosinophil-derived neurotoxin (EDN, or RNase 2) and eosinophil cationic protein (ECP, 
or RNase 3) possess anti-parasitic activity against Brugia pahangi and Brugia malayi [24]. These two 
ribonucleases are also active against respiratory syncytial virus (RSV) with a single-stranded  
RNA [128]. In addition, RNase 3 has a unique bacterial agglutinating activity [129]. In 2002, RNase 7 
was identified from human skin [40]. Remarkably, it is active against bacteria such as Mycobacterium 
vaccae and yeast, even at 4 °C [130]. Recombinant RNase 7 exhibited antimicrobial activity against 
uropathogens (E. coli, P. aeruginosa, Klebsiella pneumonia, Proteus mirabilis, E. faecalis, and 
Staphylococcus saprophyticus) [131,132]. In fact, RNase 7 is the most abundant innate defense  
peptide in the human urinary tract [132], although the contributions of other human AMPs cannot be 
ignored [56,133–135]. Human RNase 5, (also known as angiogenin or ANG) with weak RNase 
activity, is initially implicated in angiogenesis. It appears that the nucleus location is necessary for 
angiogenesis [136]. In 2003, RNase 5 was found to have a toxic effect on Gram-positive bacteria and 
fungi [41]. However, another study found little activity using a commercial material [137]. In 2006, 
RNase 8 was found to inhibit M. vaccae [138,139]. Therefore, of the eight human ribonucleases, RNases 
2, 3, 5, 7, and 8 appear to play a role in host defense. 
Psoriasin is another human protein with multiple functions. It is identical to S100A7, a protein 
member of the S100 family. Psoriasin was initially characterized as a Ca2+ binding protein with 
chemotactic property from human skin psoriatic lesions [140,141]. Subsequently, psoriasin was found 
in cancer lesions, making it a potential cancer biomarker [142]. However, the antimicrobial activity of 
psoriasin against E. coli was not demonstrated until 2005 [43]. 
Three RegIII (regenerating gene family protein III) proteins were initially identified in mice [143]. 
RegIIIα, a RegIIIγ homolog protein, was found in humans. Different from RegIIIβ from mice, human 
RegIIIα only inhibited the growth of Gram-positive bacteria such as L. monocytogenes, Listeria 
innocua, and E. faecalis [44]. 
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3. Antimicrobial and Anticancer Activities of Human Antimicrobial Peptides 
3.1. Antibacterial Activities 
Antibacterial activities of human AMPs have been mentioned in the preceding section. This section 
provides an overview of the activity spectrum of these peptides. Based on the APD [8], the majority of 
human AMPs (90 out of 103) can inhibit the growth of bacteria. They display a broad-spectrum 
activity against a variety of Gram-positive and Gram-negative bacteria. However, three human AMPs 
kill primarily Gram-positive bacteria. RNase 5 has an effect on S. pneumonia [41], while α-MSH is 
inhibitory to S. aureus [36]. A third AMP, RegIIIα, is active against L. monocytogenes, L. innocua, 
and E. faecalis [44]. In addition, ten human AMPs are inhibitory mainly to Gram-negative bacteria. 
These include hBD-26, hBD-27, human calcitermin, psoriasin/S100A7, CCL8, CCL13, CCL19, alarin, 
HMGN2, and KDAMP peptides [42,43,51,63,101]. They may control different Gram-negative pathogens. 
For example, both calcitermin and HMGN2 were active against E. coli and P. aeruginosa [101,144]. 
Alarin is active against E. coli, while the KDAMP peptides are primarily active against P. aeruginosa. 
Thus, these peptides may form the basis for developing new antimicrobials with a desired antibacterial 
activity spectrum. 
3.2. Antiviral Activity 
Of the 103 human AMPs, 16 are virucidal. They include the six well-characterized human  
α-defensins (HNP-1, HNP-2, HMP-3, HNP-4, HD-5, and HD-6), three β-defensins (hBD-1, hBD-2, 
and hBD-3), cathelicidin LL-37, histatin 5, α-MSH, elafin, SLPI, CXCL12, RNase 2, and RNase 3. 
Elafin is the major antiviral protein in cervicovaginal lavage fluid [113]. Both RNase 2 and RNase 3 
inhibit respiratory syncytial viruses (RSV) [145,146]. SLPI levels in saliva and semen, but not breast 
milk, approximate the level required for HIV-1 inhibition in vitro [147]. Although HNP-1 is a lectin 
that binds to gp120 and CD4, it shows an inhibitory effect after HIV-1 entry [148]. It also inhibits  
non-enveloped BK virus infection by aggregating virions and blocks binding to host cells [149]. Of the 
four human β-defensins, hBD-2 and hBD-3 can be induced by viral infection and block HIV replication 
by directly neutralizing the virions and through modulation of the CXCR4 coreceptor [150]. Human 
cathelicidin LL-37 is also inhibitory to HIV-1 [151,152]. Wang et al. further dissected the active 
region of LL-37. While the central fragment GI-20 showed an optimal therapeutic index, the LL-37 
core peptide FK-13 contains the minimal anti-HIV sequence [152]. In the histatin family, only a 
histatin-5-derived peptide has an effect on HIV-1 [153]. For a systematic review of AMPs with known 
anti-HIV activity, interested readers may refer to a recent review article [154]. 
3.3. Antifungal Activity 
In the APD, 58 human AMPs are fungicidal [8]. Typical examples are human α-defensins, 
cathelicidin LL-37, hepcidins, and histatins. In the case of LL-37, protease processing into fragments 
such as KS-30 and RK-31 is essential in inhibiting C. albicans [155]. In addition, the antifungal 
activity of LL-37 depends on both media and pH. Both LL-25 and RK-31 can rapidily enter the cell 
cytoplasm [156]. It is likely that these LL-37 fragments target intracellular molecules. It appears that 
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such cathelicidin fragments in human sweat play a role in human skin innate defense against fungal 
infection [155]. 
3.4. Antiparasitic Activity 
Some human AMPs also have antiparasitic properties. These include HNP-1, LL-37, granulysin, 
CCL2, CCl20, CCL28, CXCL4 (hPF4), CXCL6, CXCL9, CXCL10, RNase 2, and RNase 3. RNases 2 
and 3 might be the earliest AMP examples from humans that were demonstrated to have antiparasitic 
activity [24]. Other more recent examples are HNP-1 against the promastigotes and amastigotes forms 
of Leishmania major [157], chemokine CCL28 against Leishmania mexicana [158], LL-37 against 
Entamoeba histolytica [159], and Platelet factor 4 (hPF4) against malarial parasite Plasmodium 
falciparum [160]. These examples verify that human defense peptides also play a role in controlling 
parasite infections. 
3.5. Anticancer Activity 
There is a growing interest in developing AMPs into anticancer peptides. Magainins, cecropins, and 
defensins were all shown to have anticancer effects [161–163]. Many other AMPs possess this activity 
as well and some were discussed in previous review articles [164–166]. A more complete and updated 
list of anticancer AMPs can be searched in the APD database [8]. The 166 anticancer peptides cover 
multiple sources, including animals (105 peptides), plants (48 AMPs), bacteria (seven bacteriocins), 
fungi (one peptide), and laboratory synthesis (five peptides). 
The anticancer activities of human AMPs have not been widely evaluated since only six members 
are annotated as anticancer in the APD [8]. They are HNP-1, HNP-2, HNP-3, hBD-1, LL-37, and 
granulysin. Indeed, reduced expression of granulysin in patients is correlated with the progression of 
cancer [167]. However, the level of granulysin increased substantially in cancer cells [168]. Similar 
observations have been made with human defensins and LL-37. While HNP-1 inhibits the growth of 
human lung adenocarcinoma xenograft in nude mice [169], the same molecule can be overexpressed in  
tumors [170,171]. HBD-1 can suppress urological and prostate cancers [172,173]. In oral squamous 
cell carcinoma, hBD-1 also suppressed tumor proliferation, whereas hBD-2 and hBD-3 showed an 
opposite effect [174]. Likewise, human cathelicidin LL-37 is overexpressed in breast, ovarian, and 
lung cancers, but it suppresses tumorigenesis in gastric cancer [175]. Such a complex involvement of 
AMPs in various cancers deserves additional studies. In particular, it is important to elucidate the 
factors that trigger the overexpression of AMPs in certain cancer cells. 
Our current knowledge, however, may be utilized to our advantage. For instance, the over-expression 
of human cathelicidin LL-37 or defensins may serve as useful biomarkers for cancer diagnosis [176–178]. 
In addition, the fragments of LL-37 with demonstrated anticancer effects in vitro [179] and in vivo [180] 
might constitute useful templates for designing new anti-tumor drugs, especially those resistant to 
existing therapeutics. Anticancer AMPs can work by different mechanisms. The effects may result 
from a direct bacterial killing when bacteria could be the culprit of cancer (e.g., gastric cancer) [175]. 
AMPs may selectively kill cancer cells in part due to exposed anionic phosphatidylserines (PS) [181]. 
It is also possible that some AMPs kill cancer cells indirectly by inducing apoptosis (see below). 
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3.6. Cytotoxic Effects of Human AMPs 
It is accepted that many AMPs target bacterial membranes. While bacteria are abundant in anionic 
lipids such as phosphatidylglycerols (PG) and cardiolipin (CL) [83], human cells comprise zwitterionic 
phosphocholines (PC) and cholesterol. The differences in membranes of bacterial and human cells to a 
large extent determine cell selectivity of cationic AMPs. Indeed, among the 103 human AMPs, only 
three peptides are annotated to have cytotoxic effects on mammalian cells. In the case of LL-37, we 
found it possible to reduce the peptide cytotoxicity by decreasing peptide hydrophobicity [179,182]. 
The relatively low cytotoxicity of human AMPs makes them attractive templates for engineering  
new antimicrobials. 
In addition to membrane differences, human cells could use other mechanisms to reduce or remove 
the potential toxic effect of AMPs on themselves. By expressing a peptide called p33 on the cell 
surface, the toxic effects of human LL-37 is masked [183]. Instread of directly secreting AMPs, 
humans also release exosomes (nanovesicles enriched in host defense peptides) into the urinary tract to 
keep it sterile [184]. It may be speculated that such exosomes, similar to artificial AMP-containing 
liposomes, could be an effective way to reduce cytotoxicity to human cells. 
3.7. Other Biological Functions of Human AMPs 
In addition to antimicrobial and anticancer activities, many human AMPs possess other functions 
such as chemotaxis, apoptosis, and wound healing: 
Chemotactic activity. Currently, 35 human AMPs have chemotactic properties. Examples are 
defensins and cathelicidin LL-37. Antimicrobial chemokines were originally identified for chemotactic 
activity. A clear difference between chemokines and AMPs is the concentration needed for action. 
While the chemotactic effect needs peptides in the nM-pM range, antimicrobial action usually requires 
µM peptides [185]. Another difference between chemotactic and antimicrobial activities lies in the 
molecular target. While AMPs usually target membranes of invading bacteria, the chemotactic effects 
require the association of peptides to host cell receptors. As one example, human LL-37 achieves its 
chemotactic ability to monocytes, macrophages, neutrophils, and T cells by binding formyl peptide 
receptor-like 1 (FPRL-1) [186]. 
Apoptosis. Apoptosis is the process of programmed cell death. Different factors can trigger cell 
apoptosis. AMPs are one of these factors. Interestingly, apoptosis may be induced or suppressed by the 
same peptide depending on the biological context. Human LL-37 induces apoptosis in vascular smooth 
muscle cells, primary airway epithelial cells, oral squamous cell carcinoma SAS-H1 cells, intact rat 
aorta rings and cultured rat aorta smooth muscle cells, Jurkat T-cells and A549 cells [187–191], while 
it suppresses this process in keratinocytes and neutrophils [192,193]. As a consequence, elucidation of 
the mechanism to control apoptosis may offer new therapeutic strategies. A recent interesting finding 
is that inhibition of human LL-37-induced apoptosis by administrating urothelial glycosaminoglycan 
(GAG) analogs can prevent the development of interstitial cystitis (IC) in a mouse model [194]. LL-37 
could suppress the lipopolysaccharides (LPS)-induced apoptosis of endothelial cells, thereby 
attenuating lethal sepsis/endotoxin shock [195]. In the case of colon cancer, however, activation of 
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apoptosis suppresses tumorigenesis [196]. It seems that apoptosis requires the major antimicrobial 
region FK-16 (i.e., corresponding to residues 17-32) of human cathelicidin LL-37 [179,180]. 
Wound healing. Human host defense peptides can also promote wound healing, a process of injury 
repairs. Salivary histatin 2 can enhance fibroblast cell migration, whereas human LL-37 at 1 µM can 
induce cell migration and promote proliferation [197]. It is proposed that these peptides play a role in 
fast wound coverage. 
In summary, antimicrobial activity is a common property of human AMPs, although the in vivo 
relevance has not firmly established for each polypeptide. Furthermore, human AMPs can perform 
other functions depending on the biological context, peptide concentration, proteases, and the 
metabolic state. Under diseased conditions, AMPs may have an opposite effect (e.g., cancer 
suppression vs. progression). Understanding the elegant balance of AMPs in these processes in the 
healthy state as well as the factors that could tilt the balance to a diseased state may yield useful means 
for cancer treatment. 
4. Three-Dimensional Structures of Human Antimicrobial Peptides 
Three-dimensional structure of human host defense AMPs are helpful to understand the function of 
AMPs described above. Many short and linear antimicrobial peptides do not have a folded structure 
free in solution. However, they may become structured upon interactions with host cells by binding to 
a specific receptor to trigger the biological responses to microbial invasion. In addition, such AMPs 
may also adopt a defined structure upon association with bacterial targets such as membranes.  
The bound structure in either category is not trivial to determine. Membrane-mimetic models are 
normally utilized to determine the membrane-bound structures of receptors or AMPs. These models 
include organic solvents, detergent/lipid micelles, lipid bicelles, nanodiscs, and lipid bilayers [198,199]. 
The known 3D structures of these short peptides are primarily determined by multi-dimensional 
solution nuclear magnetic resonance (NMR) spectroscopy [199]. Some AMPs possess a folded 
structure in aqueous solutions primarily due to the structural stabilization of disulfide bonds.  
The structures of these small proteins can be determined by NMR or X-ray crystallographic methods. 
When both methods are applied, similar structures are usually found. In addition, NMR measurements 
can gain insight into protein dynamics (i.e., motions). Among the 103 human AMPs annotated in the 
APD database, 42 have a known 3D structure (27 determined by NMR and 15 by X-ray) [8]. 
Although there are different classification schemes [1–6,200], the structures of natural AMPs fall 
into four large families (α, β, αβ, and non-αβ) [201]. Peptides in the α family contain α-helical 
structure as the major secondary structure. Typical examples are human cathelicidin LL-37, histatins, 
dermcidin, and granulysin. The β family is characterized by at least a pair of two β-strands in the 
structure. Human α-defensins, hepcidins, and SLPI use this type of structure. The αβ family contains 
both α and β secondary structures, whereas the non-αβ family has neither α nor β structure (also called 
extended structures). While there are multiple structural examples for the αβ family (Table 2),  
no structural example has been found for the non-αβ family of human AMPs. In the following,  
we highlight atomic structures of human AMPs from the α, β, and αβ families. These structures are 
annotated in the APD database [8] and structural coordinates can be obtained from the Protein Data 
Bank (PDB) [202] via the APD links. 
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Table 2. Properties of selected human antimicrobial peptides with known 3D structure 1. 
APD ID Peptide name Length Net charge Pho% Boman index Structure class 
2257 Lysozyme 130 +8 40 2.28 α 
505 Histatin 5 24 +5 8 4.81 α 
780 Lactoferricin 49 +10 36 3.14 α 
310 LL-37 37 +6 35 2.99 α 
433 Dermcidin 47 −2 38 1.11 α 
1161 Granulysin 74 +11 33 3.5 α 




42 −3 45 0.77 α 
176 HNP-1 30 +3 53 1.07 β 
177 HNP-2 29 +3 51 1.17 β 
178 HNP-3 30 +2 50 1.42 β 
179 HNP-4 33 +4 51 1.4 β 
180 HD-5 32 +4 40 2.6 β 
181 HD-6 32 +2 40 1.71 β 




25 +2 52 0.89 β 
2095 SLPI 107 +12 34 1.87 β 
451 hBD-1 36 +4 36 1.3 αβ 
524 hBD-2 41 +7 36 0.9 αβ 
283 hBD-3 45 +11 33 2.87 αβ 
811 LEAP-2 40 +4 40 2.94 αβ 
2067 RNase 5 125 +11 28 2.99 αβ 
2073 RNase 7 128 +16 32 2.16 αβ 
2071 RegIIIα 149 +1 33 1.77 αβ 
2085 CCL1 73 +10 41 2.25 αβ 
2086 CCL8 75 +6 37 2.27 αβ 
2088 CCL13 75 +11 36 1.89 αβ 
2075 CCL20 69 +8 43 1.34 αβ 
2187 CCL27 56 +1 41 1.57 αβ 
2076 CXCL1 73 +6 38 1.51 αβ 
2080 CXCL10 77 +11 36 2.25 αβ 
1 Obtained from the Antimicrobial Peptide Database (http://aps.unmc.edu/AP) [8]. Peptide hydrophobic 
amino acid content (percent) is represented by pho% in the table. Protein-binding potential [1] was re-named 
as Boman index in the APD database in 2003. 
4.1. The α-Helical Family: Histatins, Cathelicidins, Dermcidin, and Granulysin 
Histatins. Histatins 1, 3, and 5 are active against C. albicans and their candidacidal activities are in 
the following order: histatin 5 > histatin 3 > histatin 1 [203]. Rai et al. investigated the relationship 
between sequence length and activity using histatin 5 as the template. They found that the C-terminal 
sequence is important [204]. P-113 with 12 residues corresponding to residues 4–15 of histatin 5 
retained anti-candida activity [205]. Using histatin 3 as a model, Zuo et al. found increased activity 
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when the active sequence was expressed in tandem (repeated once) [206]. However, duplication of the 
functional domain of histatin 5 did not enhance candidacidal activity [207]. These results suggest that 
active domain duplication is not necessary a universal strategy for activity enhancement. Histatin 5 can 
adopt a helical conformation in the presence of membrane-mimetic agents [204]. However, this helical 
structure did not appear to be essential for candidacidal activity as peptides with a less helical structure 
(achieved by proline insertion) can be equally active [208]. Histatin 5 contains a consensus sequence, 
HEXXH, which is known to bind Zinc. Zinc binding can lead to vesicle fusion and helical 
conformation as well [209]. Zinc binding actually potentiates peptide activity against gram-positive 
bacteria E. faecalis [210]. An analog of histatin 5 was found to bind DNA and have nuclease activity 
due to the synergistic oxidative and hydrolytic activities of the metal-peptide complex [211]. 
Human cathelicidin LL-37. To understand the structural basis of antimicrobial activity, 3D  
triple-resonance NMR spectroscopy was used to solve a high-quality structure for human LL-37 in  
the presence of sodium dodecyl sulfate (SDS) micelles [182]. LL-37 has a long helix covering  
residues 2–31, whereas the C-terminal tail is disordered and does not superimpose well to each other  
(Figure 1A). This structure is fully consistent with the backbone dynamics measured by an 
independent NMR experiment. This amphipathic helical region determined in SDS micelles is 
responsible for binding to bacterial outer and inner membranes. Interestingly, the LL-37 tail appeared 
to be involved in peptide aggregation [212], which influences LL-37 activity [213]. The N-terminal 
region of LL-37 is less important for antibacterial activity since LL-23, a natural fragment of LL-37, is 
only active against susceptible E. coli or S. aureus strains. The weak activity of LL-23 is attributed to a 
hydrophilic residue Ser9 that splits the hydrophobic face into two clusters [214]. This Ser9 residue also 
segregates the hydrophobic surface of LL-37 into two hydrophobic domains. It is established that the 
central helix (Figure 1B) of human LL-37 is critical for antibacterial, anti-biofilm, and antiviral 
activity (reviewed in ref [83]). 
Dermcidin. Unlike cationic cathelicidin LL-37 (net charge +6), dermcidin (DCD-1) has a net charge 
of −2. This peptide also prefers anionic membranes, however. DCD-1L, a variant with one additional 
leucine at the C-terminus, showed an enhanced affinity for membranes than DCD-1. In the membrane 
bound state, DCD-1L has a helical conformation. It is located on the membrane surface and can 
aggregate in the presence of zinc [215]. This oligomeric structure of dermcidin has recently been 
determined by X-ray crystallography [216]. A hexameric helix-bundle structure (Figure 1C) is 
proposed to insert into bacterial membrane as an ion channel. In the crystal, the Zn2+ coordinates  
with a group of acidic amino acids. It should be pointed out that the 3D structure of DCD-1L was  
also determined previously by 3D NMR spectroscopy using a 15N-labeled peptide in a 50%  
trifluoenthanol (TFE) solution. Four helical regions were identified (α1: 5–7; α2: 10–12; α3: 26–33;  
and α4: 36–45) [217]. In this case, TFE might have disrupted the oligomeric structure of dermcidin. 
There are precedents for such an effect of TFE. For example, the oligomeric structure of a K+ channel 
did not survive in TFE but retained in membrane-mimetic micelles such as SDS (reviewed  
in ref. [198]). These examples emphasize the importance of determining the 3D structure of AMPs in a 
proper environment. 
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Figure 1. Three-dimensional structures of human antimicrobial peptides from the α-helical 
family: (A) and (B) human cathelicidin LL-37 determined by NMR spectroscopy (PDB ID: 
2K6O); (C) dermcidin determined by X-ray crystallography (PDB ID, 2YMK); and (D) 
granulysin determined by X-ray diffraction (PDB ID: 1L9L). In the case of LL-37, an 
ensemble of five structures is shown to better view the disordered C-terminal tail (A), 
whereas a space-filling model is given to show the segregation of the hydrophobic surface 
(gold) into two domains (B) [182]. The longer one corresponds to the central helix which is 
important for antimicrobial, anti-biofilm and antiviral activities [83]. Images were 
generated by using the software MOLMOL [218]. Further details can be found in the text. 
 
Granulysin. Incorporation of AMPs into cytotoxic T cells might have conferred the ability to lyse 
cells. The crystal structure of granulysin is shown in Figure 1D. There are five helical regions (α1:  
2–17; α2: 23–35); α3: 39–61; α4: 66–69; α5: 71–73) [219]. The sequences of human granulysin  
(74 amino acids) and other NK-lysins share a low degree of similarity (~35%), but homologous 
modeling reveals antimicrobial features (active helices and basic residue positions) are conserved [112]. 
Although granulysin only contains two disulfide bonds, it belongs to the saposin-like protein  
family [220]. Saposin-like proteins comprise several helices usually stabilized by three disulfide  
bonds [221]. Twelve AMPs in the APD [8] from amoebozoa, nematodes, and large animals such as 
pigs are annotated to share the saposin-like protein fold [112]. To be antimicrobial, however, neither 
the entire sequence nor the protein fold is needed. For example, synthetic peptides and analogs derived 
from helices 3 and 4 are active against Vibrio cholera [222]. In addition, the peptide based on the 
helix-bend-helix motif (residues 31–50) displayed similar antimicrobial activity against 
Propionibacterium acnes (a key therapeutic target in acne) when synthesized entirely using D-amino 
acids [223]. Because short peptides can be readily synthesized, they provide useful alternatives for 
topical treatment of such bacterial infections. 
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4.2. The β Family: α-Defensins 
Alpha-defensins. Structurally, α-defensins consist of three β-strands that form a β-sheet. In the 
crystal, a dimeric structure is found for human HNP-1, where two copies of the molecule pack 
together. HNP-2 and HNP-3 have a similar structure. Thus, it is primarily due to the single amino acid 
difference in these defensins (Table 1) that influences peptide activity. With a more hydrophobic 
sequence, HNP-4 is more potent against E. coli and C. albicans than other human α-defensins [23]. 
Using a kinetic 96-well turbidimetric procedure, the relative potencies of six human α-defensins were 
compared. In the case of Gram-positive S. aureus, the activity is in the following order: HNP-2 > 
HNP-1 > HNP-3 > HNP-4. In contrast, their relative potencies against Gram-negative E. coli is  
HNP-4 > HNP-2 > HNP-1 = HNP-3 [224]. Thus, the antibacterial activities of these defensins are also 
bacteria dependent. This likely reflects the distinct differences in membranes of these organisms. The 
poor antibacterial activity of HNP-3 is not surprising considering the presence of an acidic aspartate at 
the N-terminus of the peptide, making it unfavorable to target the negatively charged surface of 
bacteria. HD-5 displayed a rather potent activity, which is comparable to HNP-2 against S. aureus and 
HNP-4 against E. coli. The higher activities of HNP-4 and HD-5 against E. coli are correlated with 
their higher net charge of +4 (Table 2). HD-6 has a poor antibacterial activity. In the crystal, it forms a 
tetrameic structure (Figure 2B) [123]. 
Figure 2. Select 3D structures of human antimicrobial peptides from the β and αβ families: 
(A) HNP-1 (dimeric crystal structure, PDB ID: 3GNY); (B) HD-6 (tetrameric crystal 
structure, PDB ID: 1ZMQ); (C) hBD-3 (NMR structure, PDB ID: 1KJ6) and RegIIIα 
(crystal structure, PDB ID: 4MTH). See the text for further details. 
 
4.3. The αβ Family: β-Defensins, Antimicrobial Chemokines, RNases, and RegIIIα 
Beta-defensins. Human β-defensins comprise both α and β structures in the same 3D fold.  
Figure 2C shows the NMR structure of human β-defensin 3 (hBD-3), which starts with a helical 
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structure followed by three beta strands [225]. NMR translational diffusion studies revealed a dimer 
for hBD-3, but a monomer for both hBD-1 and hBD-2 in solution. The stronger antibacterial activity 
of hBD-3 than either hBD-1 or hBD-2 was attributed to the dimeric structure as well as higher charge 
density on the protein surface [225]. Interestingly, the disulfide-linked form of hBD-1 is poorly active 
and became highly potent against bacteria and fungus C. albicans under reduced conditions where the 
disulfide-linked structure was disrupted [226]. It seems that the folded hBD-1 is the stored form, which 
can be transformed into an active form when needed. 
Antimicrobial chemokines. Chemokines interact with receptors to realize chemotactic functions. 
They share a similar fold consisting of a three-stranded sheet followed by one α-helix at the  
C-terminus [227–229]. The N-terminal region is frequently disordered (Figures 3A–C).  
Figure 3. 3D structures of human chemokines with antimicrobial activity. Shown are (A) 
CCL1 (NMR structure, PDB ID: 1EL0); (B) CCL8 (crystal structure, PDB ID: 1ESR); (C) 
CCL11 (NMR structure, PDB ID: 2EOT); (D) CCL21 (NMR structure, PDB ID: 2L4N); 
(E) CCL27 (NMR structure, PDB ID: 2KUM); (F) CXCL12 (NMR structure, PDB ID: 
2KOL); (G) CCL20 (crystal structure, PDB ID: 1M8A); (H) CCL13 (crystal structure, 
PDB ID: 2RA4); (I) CXCL1 (NMR structure, PDB ID: 1MSH); (J) CXCL10 (crystal 
structure, PDB ID: 1O80). 
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This can be best seen using a superimposed structural ensemble for CCL20 or CCL27 [230,231] 
determined by NMR (Figure 3D,E). The β-sheet appears to separate the N-terminal domain that 
interacts with cell receptors and the C-terminal domain that contains the antimicrobial helix for 
targeting bacterial membranes (Figure 3F) [232]. Some chemokines can also form oligomers.  
The dimeric forms of CCL20, CCL13, CXCL1, and CXCL10 [233–236] are shown in panels G to J of 
Figure 3. The dimer interface is normally composed of the C-terminal helix and strand 3. In the case of 
CCL13, however, it is the N-terminal region that occupies the interface (Figure 3H). Yung et al. found 
a direct binding of antimicrobial chemokines CXCL9 (net charge of +20) and CXCL10 (net charge +11) 
to the cell wall of S. aureus likely via the positively charged patches on these protein surfaces [237]. 
Under certain situations, the antimicrobial peptide is generated by further processing of a precursor 
protein. For example, antimicrobial thrombocidin-1 (TC-1) is produced by truncating two residues 
from the C-terminus of the parent protein NAP-2 (i.e., neutrophil-activating peptide-2), which is 
poorly active. NMR analysis revealed that the C-terminus of TC-1 is mobile. In contrast, the  
C-terminus of NAP-2 is less mobile. It was proposed that the additional two residues locked the  
C-terminus via electrostatic interactions [238]. The additional Asp residue could have masked the 
positively-charged surface of the C-terminal helix that targets bacterial membranes. Likewise, insertion 
of an acidic Glu to the N-terminal region of GF-17, a peptide corresponding to the major antimicrobial 
region of human cathelicidin LL-37 [179], substantially reduced the peptide activity [239]. 
RNases. The structures of RNase 3 (Figure 4, panels A and B) and RNase 5 (panels C and D) were 
solved by both X-ray diffraction and multi-dimensional NMR spectroscopy. Although RNase 3 is 
dimeric in the crystal, the protein fold determined by the two techniques is similar. In addition, NMR 
studies revealed two conformations for His114 of RNase 5 in solution [240]. The structures of RNase 
2 and RNase 7 are given in Figure 4 (panels E and F). Unlike chemokines discussed above, the 
antimicrobial region has been mapped to the N-terminus of RNase 7 [130,241]. In particular, a cluster 
of lysines were identified as key elements for antibacterial activity (bold in Table 1). It is proposed 
recently that the N-terminal antimicrobial function is conserved in the ribonuclease family [242]. One 
may wonder why a protein is created for bacterial defense if only part of the chain is required to kill 
pathogens. One possibility is the stability gain as part of the protein. Another possibility is that a 
folded protein structure allows for the incorporation of a variety of active sites on the protein surface. 
In certain cases, such functional sites may be overlapping [243]. In the case of RNase 7, the adjacent 
active site and antimicrobial residues allows us to propose a yet-to-be-proved “peel-and-kill” model. In 
other words, binding to bacteria by the cationic amino acids is followed by digestion of pathogenic 
nucleic acids. The multiple active sites also enable functional regulation. For example, an endogenous 
molecule can bind to RNase 7 and regulates its antimicrobial activity [244]. This could be one of the 
unique features of antimicrobial proteins distinct from small antimicrobial peptides. 
Antimicrobial lectin RegIIIα. RegIIIα (or HIP/PAP) is a C-type lectin that binds peptidoglycan 
carbohydrates of Gram-positive bacterial cell walls. The structural basis of this binding has been 
elucidated (Figure 2D) [245]. Different from other C-type calcium-dependent lectins, the binding of 
RegIIIα to peptidoglycans is calcium independent (i.e., lacking calcium-binding motif). The binding, 
however, requires the “EPN” motif and depends on sugar chain length. However, it seems that this 
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peptidoglycan binding serves as an early recognition step for the peptide action as it can create a pore 
on bacterial membranes. The structure of the oligomeric form of the protein has recently been 
determined by combining X-ray structure and electron microscopy data, providing insight into the 
lethal step of bacterial killing by this intestine lectin [246]. 
Figure 4. 3D structures of human ribonucleases with antimicrobial activity. Shown are (A) 
RNase 3 (dimeric crystal structure, PDB ID: 4A2O); (B) RNase 3 (NMR structure, PDB 
ID: 2KB5); (C) RNase 5 (crystal structure, PDB ID: 1B1I); (D) RNase 5 (NMR structure, 
PDB ID: 1AWZ); (E) RNase 2 (crystal structure, PDB ID: 2BZZ); and (F) RNase 7 (NMR 
structure, PDB ID: 2HKY).  
 
5. Mechanism of Action of Human Antimicrobial Peptides 
It is generally believed that cationic AMPs target anionic bacterial membranes. In the past years, 
significant advances have been made in elucidating the molecular targets of human AMPs. As 
described below, human AMPs can interact with a variety of molecular targets either on the cell 
surface (including membranes) or within the cells. 
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5.1. Targeting Bacterial Cell Wall 
The molecular targets of AMPs are not limited to bacterial membranes. The assembly of HD-6 on 
bacterial surface entangles bacteria, providing a new defense mechanism for human innate  
immunity [123]. HNP-1 targets lipid II to block the biosynthesis of bacterial cell walls [247].  
Böhling et al. found a close correlation of the hBD-3 activity with cell wall components [248]. A 
subsequent study corroborated the binding of hBD-3 to lipid II as well [249]. In the APD [7,8], there 
are 18 AMPs that use this mechanism to combat bacteria. Examples are nisins, mersacidin from 
bacteria, plectasin from fungi, Cg-Def, an oyster defensin [250–252]. Hence, blocking bacterial cell 
wall synthesis is a widely deployed innate defense mechanism. It is possible to identify small molecule 
mimetics that bind bacterial cell walls [253,254]. Although not discussed here, other defensins can 
directly recognize specific lipids in fungal membranes [255–257]. 
RegIII proteins are a family of lectins that can specifically recognize the carbohydrate portion of 
bacteria. While RegIIIα targets the peptidoglycan carbohydrate backbone for Gram-positive bacterial 
killing [245], mouse RegIIIβ associates with the lipid A portion of Gram-negative bacterial LPS [258]. 
In the case of murine RegIIIβ, amino acid residues in two structural motifs termed “loop 1” and “loop 2” 
are important for peptidoglycan and lipid A binding (Arg-135, Asp-142) and for the bactericidal 
activity (Glu-134, Asn-136, and Asp-142). 
It is well known that human lysozyme not only binds a single peptidoglycan chain but also cuts the 
sugar repeats, thereby inhibiting bacterial cell wall synthesis [259]. In addition, some AMPs can 
associate with cell surface proteins to interfere with the docking and entry of viruses such as human 
immunodeficiency virus type 1 (HIV-1). For example, the association of SLPI with human annexin II 
can avoid the attachment of viral lipid phosphatidylserine (PS) to the same protein in human 
macrophages [260]. 
5.2. Targeting Bacterial Inner Membranes 
Human cathelicidin LL-37 is a representative member in the helical family. It is proposed that  
LL-37 disrupts bacterial membranes. The membrane disruption of LL-37 involves at least three steps. 
First, the cationic peptide can recognize and coat the anionic surface of bacteria. With a classic 
amphipathic helical structure, this cationic peptide prefers to target anionic bacterial membranes. 
Second, LL-37 binds to the outer membranes and cross the outer membrane. Third, the peptide reaches 
the inner membrane. It initially binds to the inner membrane parallel to the surface, which is the basis 
for the carpet model [261]. At elevated concentrations, the peptide may disrupt the membranes by 
micellization. Alternatively, the peptide might take a vertical position to form a pore [262]. 
The ability of hepcidin 25 (hep-25) and its isoform hepcidin 20 (hep-20) to perturb bacterial 
membranes is markedly pH-dependent. The membrane disruption is more evident at acidic pH than at 
neutral pH. At acidic conditions, histidines become positively charged and more effective in 
membrane disruption [263]. 
While there is no agreement in the case of human LL-37 regarding the carpet or pore formation, 
recent structural determination of dermcidin provides evidence for possible pore formation in bacteria 
membranes. In the crystal structure [216], the peptide forms a hexamer, where two trimers are 
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connected by zinc (Figure 1C). It is proposed that this structure might be directly inserted into bacterial 
membranes, serving as an ion channel. 
In addition to α-defensins (HD-5 and HD-6), RegIII peptides are expressed to control the 
microbiota and keep the bacteria away from the epithelial surface of intestine. In particular, specific 
bacteria (e.g., Bifidobacterium breve NCC2950) can effectively induce the expression of RegIIIγ (an 
ortholog of human RegIIIα) in the intestine of mice via the MyD88-Ticam1 pathway [264]. RegIIIα is 
a lectin that binds to peptidoglycans of Gram-positive bacteria. However, it adopts a hexametic 
membrane-permeating pore structure to kill bacteria [246]. Such a pore is reminiscent of other pore 
structures solved for toxins [265–267]. The structure also provides a basis for selective killing of 
Gram-positive bacteria such as L. monocytogenes, L. innocua, and E. faecalis but not Gram-negative 
bacteria. This is because LPS, the major component of the outer membranes of Gram-negative 
bacteria, inhibits the pore-forming activity of RegIIIα [246]. 
5.3. Cell-Penetrating Peptides and Intracellular Targets 
There are other AMPs that may work primarily by binding DNA. Buforin is such an example [83]. 
This is not surprising because this AMP was derived from DNA-binding histone 2A. In addition, SLPI, 
a small protein that inhibits elastase and cathepsin G, displayed antibacterial activity against  
E. coli by binding nucleic acids [268]. It is also likely that AMPs kill bacteria by more than one 
mechanism. For example, human LL-37 may first damage bacterial membranes followed by DNA 
binding, leading to the shutdown of bacterial machinery [83]. 
Unlike human LL-37, histatin 5 caused only small membrane damaging effects [269]. To interpret 
the killing effect of this peptide, two models have been proposed. In the first model, treatment of  
C. albicans with histatin 5 induces the efflux of ATP and increases cell permeability to small 
molecules, leading to ion imbalance. Thus, C. albicans cells respond by activating the osmotic stress 
responding pathways to minimize ion loss. This model is supported by the fact that knocking out the 
TRK1 gene that encodes a major K+ uptake system made histatin 5 ineffective. A second model was 
also proposed based on the observation that the candida killing ability of histatin 5 is lost using a 
mitochondrial respiration mutant or after treatment with sodium azide that inhibits cellular  
metabolism [270]. In addition to the requirement of the mitochondrial respiration machinery [271], 
cellular internalization of histatins is also facilitated by peptide binding to heat shock protein Ssa2p on 
the surface of C. albicans [272]. This interference with mitochondrial respiration chain may  
be responsible for the formation of reactive oxygen species (ROS), leading to cell death [273].  
Vylkova et al. performed a DNA microarray study of the effect of histatin 5 and found that these two 
models can be unified. This is because the oxidative stress could be produced as a secondary effect of 
osmotic stress. This proposal is in line with the observation that the killing of histatin 5 is facilitated in 
the presence of an osmotic agent sorbital but not an oxidant agent H2O2 [274]. It should be mentioned 
that human GAPDH(2–32), an antifungal peptide derived from the highly conserved protein GAPDH, 
can also enter C. albicans to induce apoptosis [275]. 
As a different mechanism to combat bacterial infection, some AMPs are reported to penetrate 
immune cells and activate them to boost immune response. For example, chromagranin A-derived 
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peptides can penetrate neutrophils, bind to cytoplasmic calmodulin, and induce Ca2+ influx, leading to 
neutrophil activation and immune system augmentation [276]. 
Granulysin is an effector molecule in the cytotoxic granules of cytotoxic T lymphocytes and natural 
killer (NK) cells. It can kill intracellular pathogens in infected cells in the presence of perforin and to 
induce a cytotoxic effect against tumor cells. Although perforin and granulysin can colocalize [277],  
it is unclear how they work together in bacterial killing. A recent study reveals that perforin can form 
pores that preferentially allow the entry of cationic molecules [278]. Thus, granulysin might have 
entered the cell via the perforin pores, thereby providing yet another mechanism for intracellular 
bacterial killing by forming a molecular pair. 
6. Concluding Remarks and Potential Therapeutic Strategies 
Human antimicrobial peptides and proteins occupy an important niche in the current research on 
human host defense and innate immunity [1–6,279]. Except for antimicrobial protein lysozyme, which 
was found in 1922, most of short cationic peptides were discovered after 1980 (Table 1). By the time 
this article was written, over 100 human AMPs have been identified and characterized. They were 
either isolated from human tissues or predicted from the human genome by bioinformatics. Although 
genomic prediction constitutes an invaluable method, isolation from natural sources remains important 
in determining the exact mature form of AMPs. The discovery story of LL-37 nicely illustrates this 
point (Section 2.3). These peptides have diverse amino acid sequences (Table 1) and physical properties 
(Table 2), leading to a panel of defense molecules with varying activities (Table 1). While psoriasin 
and KDAMP primarily inhibit the growth of Gram-negative bacteria, RegIIIα is mainly active against 
Gram-positive bacteria. In addition, histatins and drosomycin-like defensin are primarily fungicidal. 
Many human AMPs such as LL-37 and defensins are broad-spectrum peptides against pathogens. 
Remarkably, human AMPs are able to hinder bacterial growth by interactions with different targets, 
ranging from surface molecules (e.g., cell walls), inner membranes, to intracellular molecules  
(Table 3). Some AMPs can interact with two or more molecules. For example, the binding of RegIIIα 
to peptidoglycans constitutes only the initial recognition step and subsequent pore formation in 
bacterial membranes could be the lethal step [246]. 
Table 3. Select human antimicrobial peptides and their proposed targets. 
APD ID AMP Structure Molecular target 
181 HD-6 β Aggregate on bacterial surface 
283 hBD-3 αβ Bacterial cell wall (lipid II) 
176 HNP-1 β Bacterial cell wall (lipid II) 
2257 Lysozyme α Cell wall carbohydrate 
2071 RegIIIα αβ Membrane pores 
310 LL-37 α Bacterial membranes and/or DNA 
433 Dermcidin α Membranes ion channel 
2017 hGAPDH(2-32) Unknown Intracellular targets of fungi 





Cytoplasmic calmodulin of 
neutrophils 
1161 Granulysin α 
Perforin generates a pore to allow 
granulysin to enter the cell and kill 
intracellular bacteria 
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For interactions with different molecules, human AMPs are capable of adopting a variety of 3D 
structures (Figures 1–4). It is clearly important to determine the structure to high quality so that the 
molecular basis of these interactions can be uncovered accurately (reviewed in ref. [52]). It is also 
important to correlate the structure with the active state of the peptide. In the case of dermcidin,  
which oligomerizes on bacterial surface, the helix-bundle structure determined by X-ray 
crystallography [216] should be more relevant. Likewise, the disulfide-bonded structure of HBD-1 
does not explain peptide activity under reduced conditions [226]. Therefore, human AMPs are diverse 
in terms of amino acid sequence, 3D structure, activity, and mechanism of action.  
Many human AMPs are currently under close examination for their functional roles as well as 
potential applications in detection and diagnosis of human diseases. The type and expression level of 
human AMPs, if accurately mapped, may have clinical relevance. A clear variation in the expression level 
of AMPs can serve as biomarkers for human diseases, such as eczema severity and cancer [280–283]. In 
addition, this remarkable array of molecules may be used for detection, imaging, and diagnosis of 
bacterial infection. An example of this application is based on the preferential association of 
Technetium-99m labeled ubiquicidin with bacteria, enabling the physician to differentiate infection 
from aseptic loosening of hip prostheses in 30 min with high accuracy [284–286]. 
The collection of human AMPs discussed herein also inspires us in developing novel therapeutics [287]. 
First, new antimicrobials may be developed using human AMPs as templates. The rationale is that 
AMPs have remained potent for millions of years and are thus less prone to microbial resistance [1–6]. 
In particular, peptides with different structural scaffolds may kill the same bacterium by different 
mechanisms (Table 3). Furthermore, the same peptide sequence can be tailored into various peptides 
that selectively target pathogens such as Gram-positive, Gram-negative bacteria, or viruses [83]. This 
is highly desirable for selective bacterial elimination without destroying the probiotic microbial flora. 
The success of this line depends on whether a selected template will achieve the desired potency in 
vivo against a target pathogen, low cytotoxicity to humans, stability to proteases, and cost-effective 
production [287]. One can also consider alternative peptide forms. For instance, a pro-drug can be used 
to reduce the cytotoxicity of AMPs if a mechanism can be found to release it when needed [288]. 
While portions of antimicrobial proteins are preferred to design novel antimicrobials [222,223,242,289], 
a whole protein may also be considered. Unlike short peptides, the folded structure of proteins confers 
stability to the action of proteases. However, the production of such a long polypeptide chain may 
require recombinant expression in bacteria or cell-free systems [199]. 
Second, new strategies are actively sought to bring the invading pathogens under control. It is 
appreciated that different receptors and signal pathways are activated in response to the invasion of 
different microbes [65]. Of outstanding interest is that non-pathogen factors can also induce AMP 
expression (Table 4). One of the earliest examples might be the light therapy invented by Niel  
Finsen [290]. The establishment of a link between light therapy, vitamin D and human cathelicidin  
LL-37 expression provides a completely different way for infection treatment. Instead of treating 
patients with traditional antibiotics, doctors may be able to use light or vitamin D [291,292]. Indeed 
using narrow-band UV B light, the level of vitamin D was increased in psoriasis patients (psoriasis is a 
common autoimmune disease on skin) [293]. In addition, other small molecules such as butyrate can 
induce LL-37 expression [294]. Components from Traditional Chinese Medicine may regulate the 
AMP expression as well [295]. These factors may induce the expression of a single peptide or multiple 
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AMPs [296]. It is also possible that certain factors can work together to induce AMP expression. 
While cyclic AMP and butyrate synergistically stimulate the expression of chicken β-defensin 9 [297], 
4-phenylbutyrate (PBA) and 1,25-dihydroxyvitamin D3 (or lactose) can induce AMP gene expression 
synergistically [294,298]. It appears that stimulation of LL-37 expression by histone deacetylase 
(HDAC) inhibitors is cell dependent. Trichostatin and sodium butyrate increased the peptide 
expression in human NCI-H292 airway epithelial cells but not in the primary cultures of normal nasal 
epithelial cells [299]. However, the induction of the human LL-37 expression may not be  
a general approach for bacterial clearance. During Salmonella enterica infection of human  
monocyte-derived macrophages, LL-37 is neither induced nor required for bacterial clearance [300]. 
Table 4. Some known factors that induce antimicrobial peptide expression  
Factor AMP induced Cells Ref 
Bacteria/LPS LL-37, HBD-2 keratinocytes [296] 
TNF-α LL-37, HBD-2 keratinocytes [296] 
UV Light LL-37, HBD-2, chemerin keratinocytes [296,301] 
Vitamin D3 LL-37 
neutrophil progenitors and 
EBV-transformed B cells 
[302,303]  
Lactose LL-37 
colonic epithelial cells 
T84, THP-1 monocytes 
and macrophages 
[304] 
Short-chain fatty acids 
LL-37; 
pBD-2, pBD-3, pEP2C, and 
protegrins 
human HT-29 colonic 
epithelial cells and U-937 





human colon cells, HCT-
116;  




human colon cells, HCT-
116 
[307] 






pBD-1, pBD-2, pBD-3 
Caco-2 cell;  
Intestinal epithelial cells 
[311] 
Butyrate LL-37 




human colon cells, HCT-
116 
[307] 
Cyclic AMP/Butyrate Chicken β-defensin 9 







bronchial epithelial cell 
line VA10  
[298] 
Finally, immune modulation peptides may find therapeutic use because they do not act on microbes 
directly and thereby are less likely to induce antimicrobial resistance [4,5]. Immune modulation is 
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activated via peptide binding to host cell receptors that initiate various signal transduction pathways. 
Recently, a natural peptide was found to have immune modulating activity but no antimicrobial 
activity [313]. Besides engineering peptides with distinct properties, there has been growing interest in 
elucidating the bacterial mechanisms in generating resistance to AMPs or by subverting host immune 
systems [314,315]. It can be anticipated that new therapeutic approaches will continue to emerge from 
our understanding of the host-pathogen interactions. All these strategies will facilitate the development 
of AMPs into novel antimicrobials to meet the challenge of antibiotics-resistant superbugs, RNA viral 
infections and difficult-to-treat cancers [287].  
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